ELISA/assay

Monkey PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) ELISA Kit

MBS2502068

48-Strip-Wells

450 USD

ELISA Kit

Monkey PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) ELISA Kit

PCSK9

proprotein convertase subtilisin/kexin type 9 preproprotein; Proprotein convertase subtilisin/kexin type 9; proprotein convertase subtilisin/kexin type 9; convertase subtilisin/kexin type 9 preproprotein; neural apoptosis regulated convertase 1; subtilisin/kexin-like protease PC9; proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9

PCSK9

PCSK9; PCSK9; FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3; NARC1; NARC-1; PC9

PCSK9_HUMAN

Monkey

692

This kit recognizes natural and recombinant Monkey PCSK9. No significant cross-reactivity or interference between Monkey PCSK9 and analogues was observed.

Store at 4 degree C.

Samples: Serum, plasma and other biological fluids. Assay Type: Sandwich. Detection Range: 0.781-50ng/mL. Sensitivity: 0.469ng/mL

Intended Uses: This ELISA kit applies to the in vitro quantitative determination of Monkey PCSK9 concentrations in serum, plasma and other biological fluids. Principle of the Assay This ELISA kit uses Sandwich-ELISA as the method. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to PCSK9. Standards or samples are added to the appropriate micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for PCSK9 and Avidin-Horseradish Peroxidase (HRP) conjugate is added to each micro plate well successively and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain PCSK9, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm +/- 2 nm. The OD value is proportional to the concentration of PCSK9. You can calculate the concentration of PCSK9 in the samples by comparing the OD of the samples to the standard curve.

31317307

NP_777596.2

NM_174936.3

Q8NBP7

20,827 Da

This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]

PCSK9: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Defects in PCSK9 are the cause of hypercholesterolemia autosomal dominant type 3 (HCHOLA3). A familial condition characterized by elevated circulating cholesterol contained in either low-density lipoproteins alone or also in very-low-density lipoproteins. Belongs to the peptidase S8 family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: EC 3.4.21.-; Cell development/differentiation; Secreted, signal peptide; Protease; Secreted. Chromosomal Location of Human Ortholog: 1p32.3. Cellular Component: Golgi apparatus; extracellular space; cell surface; rough endoplasmic reticulum; lysosome; endoplasmic reticulum; early endosome; ER to Golgi transport vesicle; extrinsic to external side of plasma membrane; perinuclear region of cytoplasm; late endosome; cytoplasm; plasma membrane. Molecular Function: very-low-density lipoprotein binding; sodium channel inhibitor activity; protein binding; protein self-association; low-density lipoprotein receptor binding; serine-type endopeptidase activity; low-density lipoprotein binding; apolipoprotein binding; apolipoprotein receptor binding. Biological Process: cholesterol metabolic process; lysosomal transport; apoptosis; positive regulation of receptor internalization; lipoprotein metabolic process; regulation of low-density lipoprotein receptor catabolic process; proteolysis; cellular response to starvation; liver development; neuron differentiation; protein autoprocessing; cholesterol homeostasis; triacylglycerol metabolic process; cellular response to insulin stimulus; neurogenesis; phospholipid metabolic process; positive regulation of neuron apoptosis; regulation of neuron apoptosis; negative regulation of receptor recycling; low-density lipoprotein receptor catabolic process; regulation of receptor activity; kidney development. Disease: Hypercholesterolemia, Autosomal Dominant, 3

48-Strip-Wells

450 USD

96-Strip-Wells

535